REGENXBIO logo
RGNX logo

REGENXBIONasdaqGS:RGNX Stock Report

Market Cap US$360.2m
Share Price
n/a
1Y-58.2%
7D-0.4%
Portfolio Value
​
View

REGENXBIO Inc.

NasdaqGS:RGNX Stock Report

Market Cap: US$360.2m

RGNX Stock Overview

A clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. More details

RGNX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Revenue is forecast to grow 33.18% per year

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years


My Notes

Capture your thoughts, links and company narrative

REGENXBIO Inc. Competitors

XOMA Royalty

NasdaqGM:XOMA

US$277.1m

MeiraGTx Holdings

NasdaqGS:MGTX

US$570.5m

iTeos Therapeutics

NasdaqGM:ITOS

US$270.7m

AnaptysBio

NasdaqGS:ANAB

US$565.7m

Price History & Performance

Summary of share price highs, lows and changes for REGENXBIO
Historical stock prices
Current Share PriceUS$7.27
52 Week HighUS$28.80
52 Week LowUS$6.56
Beta1.29
1 Month Change-8.55%
3 Month Change-24.19%
1 Year Change-58.24%
3 Year Change-71.85%
5 Year Change-81.83%
Change since IPO-76.12%

Recent News & Updates

Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again

Jan 15

Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price Following 26% Dive

Dec 28
Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price Following 26% Dive

Recent updates

Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again

Jan 15

Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price Following 26% Dive

Dec 28
Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price Following 26% Dive

REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track

Oct 31

Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?

Sep 12
Does REGENXBIO (NASDAQ:RGNX) Have A Healthy Balance Sheet?

Regenxbio: RGX-121 Could Achieve A First For Rare Neurodegenerative Disorder

Aug 06

REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Aug 04
REGENXBIO Inc. (NASDAQ:RGNX) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year

Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price

Jul 26
Revenues Working Against REGENXBIO Inc.'s (NASDAQ:RGNX) Share Price

Regenxbio: Transforming Gene Therapy With Innovative AAV Treatments, Strong Buy

Jun 11

REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

May 11
REGENXBIO Inc. (NASDAQ:RGNX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%

Apr 25
REGENXBIO Inc. (NASDAQ:RGNX) Not Doing Enough For Some Investors As Its Shares Slump 26%

Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform

Mar 11

Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers

Mar 07
Analysts Just Slashed Their REGENXBIO Inc. (NASDAQ:RGNX) EPS Numbers

Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified

Mar 05
Improved Revenues Required Before REGENXBIO Inc. (NASDAQ:RGNX) Stock's 75% Jump Looks Justified

Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Mar 02
Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Regenxbio: Robust Data, Decent Cash, Never Ending Trials, Buying At Dips

Jan 19

There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues

Dec 21
There's No Escaping REGENXBIO Inc.'s (NASDAQ:RGNX) Muted Revenues

We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully

Nov 09
We Think REGENXBIO (NASDAQ:RGNX) Needs To Drive Business Growth Carefully

Shareholder Returns

RGNXUS BiotechsUS Market
7D-0.4%2.2%-2.2%
1Y-58.2%-1.9%18.3%

Return vs Industry: RGNX underperformed the US Biotechs industry which returned -1.4% over the past year.

Return vs Market: RGNX underperformed the US Market which returned 20.8% over the past year.

Price Volatility

Is RGNX's price volatile compared to industry and market?
RGNX volatility
RGNX Average Weekly Movement9.5%
Biotechs Industry Average Movement10.9%
Market Average Movement6.0%
10% most volatile stocks in US Market17.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: RGNX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: RGNX's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2008344Curran Simpsonwww.regenxbio.com

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

REGENXBIO Inc. Fundamentals Summary

How do REGENXBIO's earnings and revenue compare to its market cap?
RGNX fundamental statistics
Market capUS$360.19m
Earnings (TTM)-US$238.80m
Revenue (TTM)US$84.33m

4.3x

P/S Ratio

-1.5x

P/E Ratio

Is RGNX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
RGNX income statement (TTM)
RevenueUS$84.33m
Cost of RevenueUS$249.31m
Gross Profit-US$164.98m
Other ExpensesUS$73.82m
Earnings-US$238.80m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-4.82
Gross Margin-195.65%
Net Profit Margin-283.19%
Debt/Equity Ratio20.5%

How did RGNX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/22 04:11
End of Day Share Price 2025/02/21 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

REGENXBIO Inc. is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Huidong WangBarclays
Alec StranahanBofA Global Research